Bayer Aktiengesellschaft (BAYRY)

OTCMKTS · Delayed Price · Currency is USD
12.95
+0.78 (6.41%)
At close: Jan 16, 2026
142.51%
Market Cap47.31B
Revenue (ttm)53.81B
Net Income (ttm)-232.31M
Shares Outn/a
EPS (ttm)-0.24
PE Ration/a
Forward PE9.16
Dividend0.02 (0.18%)
Ex-Dividend DateApr 29, 2025
Volume1,934,184
Average Volume545,114
Open12.03
Previous Close12.17
Day's Range11.95 - 13.00
52-Week Range5.29 - 13.00
Beta0.89
RSI83.48
Earnings DateFeb 25, 2026

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]

Sector Healthcare
Founded 1863
Employees 91,864
Stock Exchange OTCMKTS
Ticker Symbol BAYRY
Full Company Profile

Financial Performance

In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.

Financial numbers in EUR Financial Statements

News

Bayer : U.S. Supreme Court To Review Durnell Case In Roundup Litigation

(RTTNews) - Bayer announced that the U.S. Supreme Court has agreed to review the Durnell case in the ongoing Roundup litigation. The Court's decision follows a petition filed by Monsanto in April 2025...

2 days ago - Nasdaq

Supreme Court to hear Bayer's appeal to block thousands of Roundup weedkiller lawsuits

Bayer is arguing that consumers should not be able to sue it under state law for failing to warn that Roundup increases cancer risk because the Environmental Protection Agency has found no such risk a...

2 days ago - New York Post

Bayer (BAYZF) Sees 5% Gain as U.S. Supreme Court Agrees to Hear Roundup Appeal

Bayer (BAYZF) Sees 5% Gain as U.S. Supreme Court Agrees to Hear Roundup Appeal

2 days ago - GuruFocus

Bayer welcomes the U.S. Supreme Court decision to review the Durnell case in the Roundup™ litigation

LEVERKUSEN--(BUSINESS WIRE)--The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in ...

2 days ago - Business Wire

Supreme Court takes up Bayer’s bid to limit Roundup weedkiller liability

The Supreme Court on Friday took up a bid from Bayer to limit liability for pesticide makers, including Bayer’s Roundup weedkiller, which has become the subject of numerous cancer suits. The court sai...

2 days ago - The Hill

Bayer gains after U.S. Supreme Court grants hearing on Roundup suits

Bayer (BAYZF) shares jump after Supreme Court agrees to hear Roundup appeal, impacting 67,000 lawsuits.

2 days ago - Seeking Alpha

Supreme Court to Hear Bayer's Challenge to Roundup Weedkiller Cases

High court gives company hope in its effort to mitigate long-running litigation that has cost it billions of dollars.

2 days ago - WSJ

US Supreme Court to hear Bayer's bid to curb Roundup cases

The U.S. Supreme Court agreed on Friday to hear Bayer's bid to sharply limit lawsuits claiming that the company's Roundup weedkiller causes cancer and potentially avert billions of dollars in damages.

2 days ago - Reuters

Winter woes? Fatigue and body aches lead common complaints

Body aches (28%), fatigue (26%), feeling “off” (23%) and a runny nose (21%) are the four horsemen of a subpar day, according to new research. A survey of 2,000 adults conducted by Talker Research for ...

4 days ago - Yahoo

DAX Slips After Hitting New Record High; Bayer, RWE Post Strong Gains

(RTTNews) - German stocks climbed higher Wednesday morning with investors reacting to some encouraging corporate updates, and robust trade data from China that showed the resilience of the manufacturi...

5 days ago - Nasdaq

Bayer AG at JPMorgan Healthcare Conference Transcript

Bayer AG at JPMorgan Healthcare Conference Transcript

5 days ago - GuruFocus

Bayer targets return to mid-single-digit pharma growth by 2027

The pharmaceuticals and agriculture group Bayer aims to return its pharmaceuticals business to mid-single-digit percentage growth by no later than 2027 and lift operating margins to about 30% by 2030,...

5 days ago - Reuters

Bayer Accelerates Pharma Growth on High-Value Portfolio

SAN FRANCISCO--(BUSINESS WIRE)--On the occasion of the 44th J.P. Morgan Healthcare Conference in San Francisco, Bayer AG today unveiled the strategic focus for its Pharmaceuticals Division in 2026. Ca...

5 days ago - Business Wire

LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Bayer AG (XTER:BAYN)

LARGE CAP INTERNATIONAL PORTFOLIO Buys Shares of Bayer AG (XTER:BAYN)

5 days ago - GuruFocus

Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn't Stop for a Hot Flash' Campaign for Moderate to Severe Hot Flashes Due to Menopause

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced it has partnered with actress and menopause advocate Gabrielle Union-Wade on the ‘Life Doesn't Stop for a Hot Flash' campaign, which speaks to wo...

6 days ago - Business Wire

Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus

BERLIN & NAPLES, Fla.--(BUSINESS WIRE)--Bayer, a leading company in key areas of radiology and cardiology, and Attralus, Inc. (Attralus), a clinical stage biopharmaceutical company focused on developi...

7 days ago - Business Wire

Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress

Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next-gen genetic medicines.

9 days ago - Nasdaq

Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy

BERLIN & BOSTON--(BUSINESS WIRE)--Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaboration...

11 days ago - Business Wire

Bayer and Cradle enter collaboration to enhance AI-enabled antibody discovery and optimization

Cradle provides a scientific AI software platform focused on protein engineering Bayer continues to utilize AI in R&D, reinforcing commitment to modernize and scale its drug discovery and development ...

12 days ago - Benzinga

Bayer sues COVID vaccine makers over mRNA technology

Bayer's Monsanto sued COVID-19 vaccine makers Pfizer , BioNTech and Moderna in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology in manufacturing their vaccines, a ...

12 days ago - Reuters

Pesticide industry ‘immunity shield’ stripped from US appropriations bill

Democrats and the Make America Healthy Again movement pushed back on the rider in a funding bill led by Bayer In a setback for the pesticide industry, Democrats have succeeded in removing a rider from...

12 days ago - The Guardian

Bayer to Present Updates on Pharma Growth Strategy and Pipeline Advancements at J.P. Morgan's 44th Annual Healthcare Conference

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will participate in the 44th J.P. Morgan Healthcare Conference 2026 taking place from January 12–15, 2026 in San Francisco. Stefan Oelrich, Member of the Board o...

13 days ago - Business Wire

BAYRY's 2025 Revival: Will the Momentum Continue in 2026?

BAYRY shares have risen 121.6% in a year as new FDA approvals, pipeline wins and litigation updates fuel a sharp turnaround.

19 days ago - Nasdaq